Abstract:Abstract Background Current Phase 2a methods in tuberculosis (TB) drug development are severely limited in capturing a drug candidate’s sterilizing activity (ability to prevent TB relapse). We hypothesize that sputum-based measurements of current methods fail to capture drug activity in deep TB lesion compartments, where recalcitrant TB populations are sequestered. In our recent marmoset study, we found complementary 14-day PET/CT delta signatures across different TB lesion compartments that distinguish drugs with long-term sterilizing activity (e.g., rifampin and pyrazinamide) versus drugs with primarily early bactericidal activity (e.g., isoniazid) (Figure 1). We proceeded to evaluate this novel PET/CT Phase 2a approach among TB patients, benchmarked by drugs that are well-characterized clinically and pharmacokinetically. Methods HIV-negative patients with smear-positive pulmonary tuberculosis from Cape Town, South Africa were enrolled and randomized to receive a single drug [isoniazid (H), rifampin (R), pyrazinamide (Z), moxifloxacin (M)], a 2-drug regimen (HZ, RZ), or a 4-drug regimen (HRZE, MRZE) for 14 days in an inpatient facility. Primary data points were PET/CT scans evaluated at pretreatment baseline and treatment day 14 (and day 28 in the HRZE arm), and daily overnight sputum for early bactericidal activity measurements. Results From December 2015 to September 2017, 160 participants completed the study, from whom 340 PET/CT scans and 2,238 overnight sputum samples were collected. PET/CT scans from participants demonstrate diversity of lesion architecture and inter-individual variation in PET/CT changes over 14 days of treatment (Figure 2). A preliminary computational algorithm and first- and second-order PET/CT statistics have been developed for initial segmentation and TB lesion categorization of all study scans. Derivation of radiologic signatures by analysis of 14-day PET/CT changes across each lesion type is ongoing; blinded prediction of each participant’s treatment arm based on these signatures is expected by third-quarter 2018. Conclusion If successful, these signatures may be applied within a 14-day Phase 2a framework to evaluate new TB drug candidates and construct TB drug regimens with complementary lesion pharmacokinetics. Disclosures All authors: No reported disclosures.

Targeted Theranostics for Tuberculosis: A Rifampicin-Loaded Aggregation-Induced Emission Carrier for Granulomas Tracking and Anti-Infection.

121. Improving Predictive Value of Phase 2a TB Drug Development Models Through PET/CT Imaging (nexgen EBA)

Photoclick Reaction Constructs Glutathione-Responsive Theranostic System for Anti-Tuberculosis

Photothermal Therapy of Tuberculosis Using Targeting Pre-Activated Macrophage Membrane-Coated Nanoparticles

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections.

NIR‐II AIE Luminogen‐Based Erythrocyte‐Like Nanoparticles with Granuloma‐Targeting and Self‐Oxygenation Characteristics for Combined Phototherapy of Tuberculosis

Photothermal and host immune activated therapy of cutaneous tuberculosis using macrophage targeted mesoporous polydopamine nanoparticles

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection

Lipophilic AIEgens as The "Trojan" Sniper with Discrepant Efficacy in Tracking And Treatment of Mycobacterial Infection

The past, present and future of tuberculosis treatment.

Seeing is believing: Efficiency evaluation of multifunctional ionic-dependent AIEgens for tuberculosis

An Oxygen Supply Strategy for Sonodynamic Therapy in Tuberculous Granuloma Lesions Using a Catalase-Loaded Nanoplatform.

Macrophage Targeted Iron Oxide Nanodecoys Augment Innate Immunological and Drug Killings for More Effective Mycobacterium Tuberculosis Clearance.

Lipophilic AIEgens As the "trojan Horse" with Discrepant Efficacy in Tracking and Treatment of Mycobacterial Infection.

Nanotechnology‐Based Targeted Drug Delivery: An Emerging Tool to Overcome Tuberculosis

Macrophage targeted graphene oxide nanosystem synergize antibiotic killing and host immune defense for Tuberculosis Therapy

High-throughput fluorescent screening of β-lactamase inhibitors to improve antibiotic treatment strategies for tuberculosis

Nanomaterial-mediated host directed therapy of tuberculosis by manipulating macrophage autophagy

Whole-animal Imaging of Bacterial Infection Using Endoscopic Excitation of Β-Lactamase (Blac)-Specific Fluorogenic Probe

Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

Current progress of functional nanobiosensors for potential tuberculosis diagnosis: The novel way for TB control?